Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-219829
Filing Date
2026-05-12
Accepted
2026-05-12 17:11:41
Documents
77
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q bbot-20260331.htm   iXBRL 10-Q 2604783
2 EX-2.1 bbot-ex2_1.htm EX-2.1 1308471
3 EX-2.2 bbot-ex2_2.htm EX-2.2 41314
4 EX-10.1 bbot-ex10_1.htm EX-10.1 372741
5 EX-10.35 bbot-ex10_2.htm EX-10.2 460305
6 EX-10.3 bbot-ex10_3.htm EX-10.3 27747
7 EX-19.1 bbot-ex19_1.htm EX-19.1 171303
8 EX-31.1 bbot-ex31_1.htm EX-31.1 17457
9 EX-31.2 bbot-ex31_2.htm EX-31.2 17563
10 EX-32.1 bbot-ex32_1.htm EX-32.1 10133
11 EX-32.2 bbot-ex32_2.htm EX-32.2 10141
  Complete submission text file 0001193125-26-219829.txt   12727998

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT bbot-20260331.xsd EX-101.SCH 1376073
81 EXTRACTED XBRL INSTANCE DOCUMENT bbot-20260331_htm.xml XML 1750957
Mailing Address 256 E. GRAND AVENUE, SUITE 104 SOUTH SAN FRANCISCO CA 94080
Business Address 256 E. GRAND AVENUE, SUITE 104 SOUTH SAN FRANCISCO CA 94080 857 702 0377
BridgeBio Oncology Therapeutics, Inc. (Filer) CIK: 0001869105 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41955 | Film No.: 26969794
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)